GUANGZHOU OULEDI TRADING CO., LTD. – Trademark Portfolio

Entity Type: 99

GUANGZHOU OULEDI TRADING CO., LTD. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include ONLEDY, WISKANUTR, VERWANDRIC, and WALGHYDRIC. The owner is based in GUANGZHOU.

ROOM 358, 403, 4TH FLOOR, BUILDING 1, NO. 19 GUANGSHENG ROAD, NANSHA STREET, NANSHA DISTRICT, GUANGZHOU CITY

GUANGZHOU , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

GUANGZHOU OULEDI TRADING CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does GUANGZHOU OULEDI TRADING CO., LTD. have?

GUANGZHOU OULEDI TRADING CO., LTD. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does GUANGZHOU OULEDI TRADING CO., LTD. file in?

GUANGZHOU OULEDI TRADING CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are GUANGZHOU OULEDI TRADING CO., LTD.'s most well-known trademarks?

GUANGZHOU OULEDI TRADING CO., LTD.'s registered trademark portfolio includes well-known marks such as ONLEDY, WISKANUTR, VERWANDRIC, and WALGHYDRIC. These are among 4 currently registered trademarks in the portfolio.

What is GUANGZHOU OULEDI TRADING CO., LTD.'s trademark registration success rate?

GUANGZHOU OULEDI TRADING CO., LTD. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.